2017 Election for ISSCR Board of Directors 

Cast your ballot for the 2017 ISSCR Board of Directors. 

Elections are now open online through 23 February 2017.

ISSCR full and trainee members are invited to vote. This is your opportunity to make a difference. Help shape the future of your Society by voting in the 2017 ISSCR Board of Directors election.

Have you renewed your membership? Not a member? Join now.

The ISSCR Board of Directors consists of 22 members, and includes the president, president elect, vice president, past president, clerk and treasurer. Nominations for the Board of Directors were made by ISSCR members in October/November 2016. Candidates have been slated by the Nominating Committee with an emphasis on scientific authority and to keep the overall international diversity of the board. 

Online voting will be open 20 January – 23 February 2017.  Current full and trainee members are invited to vote for: 

  1. Vice President
  2. Five new members to the ISSCR Board of Directors

New officers will begin their terms following the ISSCR 2017 Annual Meeting, 14–17 June in Boston, Massachusetts, USA. For more information, contact Lynnea Brand at lbrand@isscr.org

1. Candidates for Vice President

Return to top
Deepak Srivastava photo

Deepak Srivastava, MD

Deepak Srivastava serves as Director of the Roddenberry Stem Cell Center at Gladstone and the Gladstone Institute of Cardiovascular Disease. At the University of California, San Francisco (UCSF), he is also a Professor in the Departments of Pediatrics, and Biochemistry & Biophysics, and is an attending pediatric cardiologist in UCSF’s Benioff Children’s Hospital.

Important Issues on the Horizon for ISSCR

It would be an honor and a privilege to serve the ISSCR as Vice-President. We are in a time of unprecedented potential using stem cell technologies to address many of mankind’s most devastating diseases. In some cases advances in knowledge still require deeper mechanistic insight to achieve effective translation, while more mature discoveries require rigorous testing in well-designed clinical trials. Challenges for the ISSCR during this time of great opportunity will be to facilitate rapid scientific discovery and open international exchange, provide effective advocacy for research funding and ethical deployment of revolutionary technologies, and ensure worldwide coordination of regulatory reform to achieve a balance of safe, yet urgent, advancement of clinical trials. ISSCR is the singular international organization that can represent our entire community and must lead in each of these areas for our field to most effectively harness the promise of stem cell biology to alleviate human suffering.


Dr. Srivastava’s laboratory revealed how cardiac chamber-specific gene networks are established at the transcriptional level and are integrated with signaling pathways. His laboratory used human genetics to demonstrate that a decrease in dosage of some of these cardiac developmental regulators can cause human cardiac malformations, and has discovered the underlying mechanisms using deep network interrogation of human induced pluripotent stem cells. In studying the regulation of gene dosage, his lab described the first known biological role of a microRNA in the mammalian system, ultimately revealing a network of microRNAs that titrate the dose of key cardiac gene networks that dictate cell fate and differentiation. Dr. Srivastava’s lab has leveraged the body of knowledge from cardiac developmental biology to reprogram non-muscle cells in the mouse heart directly into cells that function like cardiomyocytes, effectively regenerating heart muscle in the setting of heart failure. This paradigm of harnessing endogenous cells in situ to regenerate organs may be broadly applicable to other organs.

Such approaches to understand human disease promise to yield new therapies. Dr. Srivastava has co-founded two biotechnology companies, iPierian and Tenaya Therapeutics, to help find new cures for many human diseases using cellular reprogramming technologies. A Phase I clinical trial for one of the developmental genes whose role he discovered, Thymosin b4, has been completed for patients suffering heart disease. As Program Chair for the 2016 ISSCR Annual Meeting, Dr. Srivastava emphasized the importance of basic research to develop a strong pipeline of knowledge, while also highlighting the rapidly advancing areas of clinical translation aimed at deadly human diseases with unmet needs.

Before joining Gladstone in 2005, Dr. Srivastava was a Professor in the Department of Pediatrics and Molecular Biology at the University of Texas Southwestern (UTSW) Medical Center in Dallas. He has received numerous honors and awards, including election to the American Society for Clinical Investigation, the American Academy of Arts and Sciences, the American Association for the Advancement of Science and the National Academy of Medicine. Dr. Srivastava’s laboratory has trained more than 50 postdoctoral fellows and graduate students.

Dr. Srivastava completed his undergraduate degree at Rice University, medical training at the University of Texas, and his residency in the Department of Pediatrics at UCSF. He also did a fellowship in pediatric cardiology at the Children’s Hospital of Harvard Medical School and a postdoctoral fellowship at the M.D. Anderson Cancer Center, before joining the faculty at UTSW in 1996.

Dr. Srivastava is a member of the ISSCR Board of Directors, Stem Cell Reports Editorial Board, chaired the 2016 Annual Meeting Program Committee, was the organizer of the International Symposium 2012 Roddenberry, was a member of the 2013 and 2010 Annual Meeting Program Committees, Communications Task Force, Clinical Translation Committee and has served as an abstract reviewer.

Owen N. Witte MD

Owen N. Witte, MD

Owen Witte is a University Professor of Microbiology, Immunology and Molecular Genetics at UCLA and holds the President's Chair in Developmental Immunology.  He is also the Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

Important Issues on the Horizon for ISSCR

As the stem cell research field has matured and examples of scientific advances are being translated to the clinic it becomes even more critical to dissociate stringent clinical trials and new FDA approved medicines from the myriad examples of bogus “stem cell therapies” now being sold to the public.  ISSCR has had a clear mission to oppose stem cell advertised medical therapies that are not based on rigorous data.  Support for comparative studies of stem cells at all stages of development from human and other species is essential to move the field forward. As gene editing techniques are applied to science and medicine, ISSCR must vigorously participate in guiding the regulatory standards that will control their use in research and medicine.  


Owen Witte received his undergraduate degree from Cornell and his MD from Stanford University. He completed postdoctoral research at MIT then joined the faculty at UCLA.

Dr. Witte has made significant contributions to the understanding of human leukemias, immune disorders, and epithelial cancer stem cells. His work includes the discovery of tyrosine kinase activity for the ABL gene and the demonstration of the BCR-ABL oncoproteins in human leukemias. This has had practical impact in leading to the development of kinase targeted therapy as an effective treatment for these leukemias and other cancers. His work also led to the co-discovery of Bruton’s tyrosine kinase (BTK) which is required for normal B-lymphocyte development, and when mutated leads to X-linked agammaglobulinemia, a form of immune deficiency. New inhibitors for BTK are entering clinical practice for the treatment of certain lymphomas and leukemias. Recent work has concentrated on defining the stem cells for epithelial cancers of the prostate and other organ sites to help define new types of therapy for these diseases.

Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. He has received many awards for his research including most recently the AAMC Award for Distinguished Research in Biomedical Sciences (2016) and the Stanford Medical School Kornberg-Berg Lifetime Achievement Award in Biosciences (2016). He currently serves on several editorial and advisory boards. Dr. Witte previously served on the Board of Directors for the American Association for Cancer Research. He was also re-appointed for his 2nd term by President Obama to the President’s Cancer Panel.

Dr. Witte has extensive experience consulting in the biotech and pharmaceutical industry. Most recently, he is a Founder and Chairman of the Scientific Advisory Board of Kite Pharma, and a Founder and member of the Board of Directors of Trethera Corporation.

Dr. Witte was a member of the 2015 ISSCR Annual Meeting Program Committee. 

2. Candidates for the Board of Directors

Return to top
Roger Barker

Roger Barker, BA MBBS MRCP PhD FMedSci

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge.


For the last 25 years Dr. Barker has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new therapies into the clinic by aligning new therapies to the optimal patient groups. In this respect he has been heavily involved in gene and cell based trials for patients with these conditions and currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD, following on from an earlier MRC funded trial using similar tissue in HD. 

Dr. Barker is part of a new EU project (NeuroStemCellRepair) and a global initiative (GFORCE-PD) that is seeking to take stem cells to trial in these disorders. He is currently is Co-Editor in Chief of the Journal of Neurology and sits on the editorial board of many other journals. He has just stepped down as the chairman of the ERC Advanced grants in Neuroscience committee, and is on the research advisory board of the Cure PD Trust and Parkinson's UK as well as advising government on regenerative medicine in the UK. In 2015 he was elected a Fellow of the Academy of Medical Sciences.

Dr. Barker has been involved with helping write the guidelines from the ISSCR on the clinical translation of stem cells and in 2016 took over as chairman of the Clinical Translation Committee at the society. He has published over 400 papers and is heavily involved in patient and public engagement and in taking clinical science out to the public and patient communities.

Cédric Blanpain, MD PhD

Cédric Blanpain is a full professor and WELBIO investigator at the Université Libre de Bruxelles.


Dr. Blanpain graduated as a Medical Doctor (MD) and is board certified in internal medicine from the Université Libre de Bruxelles, Belgium. He performed his PhD in the laboratory of Marc Parmentier, where he studied how CCR5 interacts with its natural ligands and the HIV envelope to mediate viral entry. He started his career in stem cell (SC) biology as a postdoctoral fellow in the laboratory of Elaine Fuchs, Rockefeller University, where he developed new methods to isolate and characterize hair follicle SC and study the mechanisms regulating their function.

Dr. Blanpain started his own lab at the Université Libre de Bruxelles in October 2006. His research group uses lineage-tracing approaches to study the role of SCs during development, homeostasis and cancer. His group uncovered the role and the mechanisms by which Mesp1 acts as a master regulator of cardiovascular progenitor specification and differentiation. His group uncovered the existence of rapidly cycling progenitors that ensure the daily maintenance of the epidermis and SCs that contribute to wound healing. They uncover a novel paradigm of lineage segregation in different glandular epithelia, by showing that the different mammary lineages originate from multipotent embryonic progenitors that are replaced after birth by distinct unipotent SCs whereas prostate postnatal development is mediated by multipotent SCs that become lineage restricted in adult. For the vast majority of cancers, the cell at the origin of tumor initiation is still unknown. His lab was pioneered in using mouse genetics to lineage trace the origin of epithelial cancers. They identified the cancer cell of origin and the mechanisms regulating the early steps of tumor initiation in skin basal cell carcinoma, skin squamous cell carcinoma and PIK3CA mediated mammary tumors. His lab uses different approaches including clonal analysis by lineage tracing and lineage ablation to unravel the mode of tumour growth within their natural environment. Using genetic gain and loss of function in vivo, they uncovered the role of the perivascular niche and different transcription factors including Sox2 in regulating skin tumor stemness. These recent years, he wrote many reviews on epithelial stem cells and cancer for leading scientific journals.

Dr. Blanpain received several prestigious and highly competitive awards for young investigators including a career development award of the HFSP, EMBO Young investigator award, ERC starting and ERC consolidator grants, the outstanding young investigator award of the ISSCR 2012, the Liliane Bettencourt award for life sciences 2012. He has been elected member of the EMBO in 2012, the Belgian Royal Academy of Medicine, and the Academia Europa. He is member of several International Scientific Advisory Boards of leading Universities.

Dr. Blanpain has been very active and dedicated to the ISCCR and other scientific societies. He has been co-chair of the junior investigator committee (2010-2013) and member of the committee responsible for restructuring the ISCCR website (2010-2013). He is currently member of the ISCCR international affair committee (2014-) and he is the first president of the Belgian Society for Stem Cell Research (2015-).

Dr. Blanpain serves as a member of the Stem Cell Reports Editorial Board, was a member of the Regional Forum 2013 Florence organizing committee and is an ISSCR abstract reviewer.

Konrad Hochedlinger, PhD

Konrad Hochedlinger, PhD, is a Professor of Stem Cell and Regenerative Biology at Harvard University and a member of the Department of Molecular Biology and Center for Regenerative Medicine at the Massachusetts General Hospital.


Dr. Hochedlinger completed his undergraduate training at the University of Vienna and his graduate and post-graduate training with Dr. Rudolf Jaenisch at MIT. Dr. Hochedlinger’s lab studies the molecular mechanisms that control normal development, tissue regeneration and cancer. His lab has made important contributions to our understanding of how transcription factors rewire the epigenetic state of cells during cellular reprogramming and related fate transitions. Dr. Hochedlinger is the recipient of the ISSCR Outstanding Young Investigator Award, the Harland Winfield Mossman Award for Developmental Biology and an HHMI Early Career Award.

Dr. Hochedlinger was a member of the ISSCR Publications Committee and has served as an abstract reviewer.

Ruth Lehmann, PhD

Ruth Lehmann is an investigator of the Howard Hughes Medical Institute and the Chair of the Department of Cell Biology at NYU School of Medicine. Dr. Lehmann directs the Skirball Institute and the Helen and Martin Kimmel Center for Stem Cell Biology.


Dr. Lehmann’s research focuses on germ cells, the only stem cells in the body able to give rise to a new generation. Her lab uses systematic, unbiased genetic approaches in Drosophila to understand how germ cells are specified in the early embryo and how they maintain the potential for totipotency while differentiating into egg and sperm in the adult. Born in Cologne, Germany, Dr. Lehmann studied biology at the universities of Freiburg and Tübingen, Germany.  She received her Ph.D in the laboratory of Dr. Christiane Nüsslein-Volhard at the Max Planck Institute for Developmental Genetics in Tübingen, Germany in 1985. After postdoctoral training at the Medical Research Council in Cambridge, UK she joined the Whitehead Institute and the faculty of MIT in 1988. She identified the RNA regulators Nanos and Pumilio and discovered that RNA is translationally repressed during transport but becomes activated once localized. In 1996, Dr. Lehmann was recruited to the Skirball Institute at NYU School of Medicine.  Here her lab began to unravel cues that control of germ cell migration by showing how lipid signaling affects germ cell migration and started to work on aspects of germ line stem cell behavior.  Presently, the lab is focused on how protein and RNA components are spatially organized within RNP granules and how mitochondria are transmitted through the germ line. In genome wide-screens for regulators of germ line stem cells, the lab identified new regulatory networks that influence the self-renewal versus differentiation decision and new mechanisms by which transposable elements are controlled in the germ line. Dr. Lehmann is a member of the American Academy of Arts Sciences and the National Academy of Sciences. She was the 2011 recipient of the Conklin Medal of the Society of Developmental Biology and was elected Associate (foreign) Member of EMBO in 2012. Dr. Lehmann was the President of the Society of Developmental Biology and the Drosophila Board, she served on the councils of the National Institute of Child Health and Development and the American Society of Cell Biology, and is a member of several advisory boards in the US and Europe. As the founding director of two graduate training programs, Dr. Lehmann is committed to training the next generation of stem cell scientists. In her role as chair and director she is engaged in mentoring junior faculty and fostering collegial workspaces.

Dr. Lehmann was a member of the 2012 ISSCR Annual Meeting Program Committee and has served as an abstract reviewer.

Melissa Little, BS PhD GAI

Melissa Little is the Theme Director of Cell Biology at the Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne and is a Professor in the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia.


For more than 20 years Melissa Little’s research has focussed on the molecular basis of kidney development, renal disease and repair. She is internationally recognised for her work on the systems biology of kidney development and also her pioneering studies into potential regenerative therapies in the kidney. Her work on the developing kidney has driven studies into the recreation of nephron stem cell populations via transcriptional reprogramming and directed differentiation of pluripotent stem cells. As a result, her research now focuses on the generation of mini-kidneys from stem cells for use in drug screening and disease modelling and bioengineering.

A Fellow of the Australian Academy of Health and Medical Sciences, Professor Little’s work has been recognised by many awards, including the GlaxoSmithKline Award for Research Excellence (2005), AAS Gottschalk Medal in Medical Sciences (2004), Eisenhower Fellowship (2006), ANZSCDB Presidents Medal (2015) and a Boerhaave Professorship, Leiden University (2015).

A graduate of the Australian Institute of Company Directors, she founded Nephrogenix Pty Ltd and from 2007-2008, she served as the Chief Scientific Officer at the Australian Stem Cell Centre. Melissa is President of the Australasian Society for Stem Cell Research and Program Leader of Stem Cells Australia. She currently serves as a Special Editor for Development and on the editorial board of the Journal of the American Society for Nephrology, Kidney International and Developmental Biology.

Dr. Little is the chair of the 2018 ISSCR Annual Meeting Program Committee, was a member of the 2010 Annual Meeting Program Committee, and has served as an abstract reviewer and serves on the Membership Committee.

Chuck Murry, MD PhD

Chuck Murry is the Woods Professor of Pathology, Bioengineering and Cardiology, and the Director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington (UW) in Seattle.


Dr. Murry is a pathologist and stem cell biologist leading the UW Medicine Heart Regeneration Program. He uses stem cell systems to study cardiovascular development, tissue formation, and mechanisms of disease. 

Dr. Murry was born in Bismarck, North Dakota. After completing his bachelor’s degree in chemistry at the University of North Dakota, he undertook the MD-PhD training at Duke University. His PhD thesis included the discovery of ischemic preconditioning, a stress response that provides the most powerful protection against cell death identified to date. He did residency training in Pathology at the University of Washington, followed by a clinical fellowship in cardiovascular pathology and a research fellowship in vascular biology. He joined the UW faculty in 1996, reached full professor in 2004, and went on to found the UW’s Center for Cardiovascular Biology in 2005 and Institute for Stem Cell and Regenerative Medicine in 2008.  

The Murry laboratory pioneered the use of human pluripotent stem cells for heart regeneration and was the first to form human myocardium in experimental animals using stem cell transplantation. He showed that this new myocardium becomes vascularized, survives long term, beats in synchrony with the heart, and enhances function in small animals and non-human primates. A clinical trial of human cardiomyocyte transplantation is planned for 2019. Dr. Murry is also known for his seminal contributions to the role of Wnt signaling in cardiac differentiation, discovered chromatin signatures that identify novel developmental regulators, identified cross-talk between cardiomyocytes and stomal-vascular cells in 3D tissue, and developed techniques to enhance the maturation of stem cell-derived cardiomyocytes for disease modeling and drug screening.

Dr. Murry has been recognized with several awards including the Burroughs-Wellcome Career Award in the Biomedical Sciences in 1996 and a Presidential Early Career Award in Science and Engineering in 2000. Since 2013, he has been elected fellow of the American Association for the Advancement of Science, the Association of American Physicians, and the American Institute for Medical and Biological Engineering. Dr. Murry has served as a councilor for the International Society for Heart Research and the Society for Cardiovascular Pathology. He has mentored over 100 undergraduate, pre and post-doc trainees.  In addition, he has given numerous seminars and authored nearly 200 publications and book chapters. Dr. Murry has served on multiple editorial boards as well as review boards for NIH and private foundations. 

Since 2013, Dr. Murry has served on the ISSCR’s Task Force to revise the Guidelines for Stem Cell Research and Clinical Translation, and with their recent publication, he has shifted his focus to the ISSCR’s Clinical Translation Committee. Dr. Murry was also a member of the 2015 ISSCR Annual Meeting Program Committee. He would be honored to continue this line of service on the ISSCR Board of Directors. 

Duanqing Pei, PhD

Duanqing Pei is Professor of stem cell biology and also serves as Director General at the Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou, China.


Dr. Pei obtained his PhD from the University of Pennsylvania in 1991 and then trained as a postdoctoral fellow at the University of Michigan before becoming a tenure-track assistant professor and tenured at the University of Minnesota School of Medicine. He joined the Medical Faculty at Tsinghua University in Beijing China in 2002 and moved to GIBH in 2004. 

Dr. Pei studied the transcription regulation of hepatitis B virus (HBV) for his Ph.D. thesis and worked on ECM remodeling as a postdoc and faculty member in the US. Upon return to China, he started to focus on stem cells by working on pluripotency first and then reprogramming.  The Pei lab in Tsinghua began to publish in the stem cell field on the structure and function of Oct4, Sox2, FoxD3, Essrb, and Nanog, and their interdependent relationship in regulating pluripotency. At GIBH, the Pei lab was the first in China to create mouse iPSCs using a non-selective system, and then improved the iPS process systematically.  The Pei lab subsequently disseminated the iPS technology in China by providing not only resources, but also training workshops. 

Dr. Pei and colleagues show that 1) a mesenchymal to epithelial transition (MET) initiates the reprogramming process, 2) vitamin C is a potent booster for iPSC generation through both DNA and histone demethylases and 3) a new 6 factor (6F) combination can reprogram MEFs into iPSCs.

Dr. Pei is active in national and international policy discussion, for example, the International Summit on Human Gene Editing organized by the US National Academies of Science and Medicine, Royal Society of London and Chinese Academy of Sciences and now continues to be a member of its study group. He co-founded the Gordon Research Conference on “Genome Architecture in Cell fate and Diseases”.

Dr. Pei has served as a member of the ISSCR Public Policy Committee, Awards Committee and Clinical Translation Committee and was a member of the 2014 ISSCR Annual Meeting Program Committee and has served on the organizing committees for the International Symposium 2015 Suzhou and the International Symposium 2017 Guangzhou.  Dr. Pei has also served as an abstract reviewer.

Frederic de Sauvage, PhD

Frederic de Sauvage is Vice President of Research-Molecular Oncology at Genentech.


Dr. de Sauvage obtained his PhD summa cum laude from the Catholic University of Louvain in Belgium. He joined the laboratory of David Goeddel at Genentech as a postdoctoral fellow in 1990 and was hired as a Scientist in 1992. In 1994, Dr. de Sauvage's team at Genentech discovered Thrombopoietin (TPO), the long sought physiological regulator of platelet production. His laboratory made many contributions to the field of hematopoeisis before switching its focus to the Hedgehog pathway in the late 1990s. His work led to the development of vismodegib, the first Hedgehog Pathway Inhibitor approved for the treatment of metastatic or locally advanced basal cell carcinoma (BCC) and is currently in clinical trials for the treatment of other cancers. Dr. de Sauvage has recently turned his attention to studying the role of intestinal stem cells in tumorigenesis. In 2011 he received the Achievement in Advancing Targeted Therapies for Cancer & Melanoma Award from the American Skin Association in recognition of his work for patients with BCC. He was elected a fellow of the American Association for the Advancement of Science in 2016.

Dr. de Sauvage has served as an ISSCR abstract reviewer.

Yukiko Yamashita, PhD

Yukiko Yamashita is an associate professor at the University of Michigan Ann Arbor and an investigator of the Howard Hughes Medical Institute.


Dr. Yamashita obtained her PhD from Kyoto University, Japan, completed the postdoctoral fellowship with Minx Fuller at Stanford University (2001-2006), She started her own laboratory at the University of Michigan in 2007. 

Dr. Yamashita studies the cellular mechanisms of stem cell self-renewal and differentiation, with a particular focus on understanding how adult stem cells divide asymmetrically, giving rise to one stem cell and one differentiating cell, to maintain tissue homeostasis. She has shown how general cell biological processes, such as cell cycle regulation and cytoskeleton organization, which are shared by many other non-stem cells, are modulated in a stem cell-specific manner to fulfill stem cell function. Another rising interest is the role of satellite DNA, a highly repetitive and non-coding element, in eukaryotic genomes during stem cell divisions and germ line lineages. 

Dr. Yamashita serves on the editorial boards of eLife, Molecular Biology of the Cell, PLoS Biology and Scientific Reports. Yamashita is a recipient of 2008 Searle Scholar Award, 2009 ASCB WICB junior award, 2011 MacArthur Fellowship, 2016 Tsuneko and Reiji Okazaki Award.

Dr. Yamashita was a member of the 2011 ISSCR Annual Meeting Program Committee and has served as an abstract reviewer.

Shosei Yoshida, MD PhD

Shosei Yoshida is a full professor of Division of Germ Cell Biology at the National Institute for Basic Biology (NIBB), Okazaki, Japan.


Shosei Yoshida is studying the mouse spermatogenic stem cells. He graduated the University of Tokyo Faculty of Medicine in 1991. He completed his graduate training at the Institute of Medical Sciences, the University of Tokyo, and received Ph.D. in 1995, from the study on the regulatory mechanism of skeletal muscle differentiation and the formation of “reserve cells”. He then moved to the field of mouse spermatogenic stem cells when he was appointed an assistant professor at Osaka University and then Kyoto University. In 2008, Dr. Yoshida moved to National Institute for Basic Biology (NIBB), Okazaki, Japan, as a full professor of Division of Germ Cell Biology, to extend his study on spermatogenesis and its stem cells. 

Dr. Yoshida’s research interest is in particular on the stem cell identity and their dynamics, with regard to their localization, motion, and fate behaviors. He also investigates the molecular and cellular nature of stem cell niche. To this end, his group has been taking advantages of combinatory approach, involving a live-imaging study that he uniquely developed, clonal fate analysis of pulse-labeled stem cells, and biophysical analysis through a fruitful collaboration with Ben Simons.

Dr. Yoshida discovered the reversible potential of differentiation-destined spermatogonia back to self-renewing pool, whose contribution becomes prominent upon regeneration or post-transplantation repopulation. He also characterized the vasculature-associated stem cell niche in seminiferous tubules. His intravital live imaging revealed the breakdown of intercellular bridges between spermatogonia, that have been believed to be a perdurable structure, and the active stem cell migration over the tissue as well. Dr. Yoshida’s discoveries lead to dynamical and stochastic stem cell models underlying the long-term homeostasis in tissues harboring a facultative stem cell niche.

Dr. Yoshida has served as an ISSCR abstract reviewer.

International Society for Stem Cell Research
5215 Old Orchard Road, Suite 270
Skokie, Illinois, USA 60077
+1 224-592-5700